by International Biophysics
Value Proposition for
DME’s and Patients
International Biophysics brings to market innovative, disruptive
medical devices and technologies that improve treatment
therapies and patient outcomes. Centered on a precision
ISO 13485 certified, FDA registered, quality controlled
manufacturing facility in Austin, Texas, International Biophysics
has a 25 year pedigree of successful medical product and
technology launches around the globe. We discover, make and deliver science inspired medical
innovation, creating custom pathways to success in multiple
markets, spanning direct-from-manufacturer sales to product
line and company spin-off acquisitions.
2
AffloVest: DME Value Proposition
With all the reductions in reimbursement DME’s
will have to struggle with in 2016, how are you
going to grow your business now?
Let International Biophysics help you grow by introducing you to the AffloVest and the
E0483 High Frequency Chest Wall Oscillation market (HFCWO). The HFCWO market is
the highest capped rental market in respiratory.
Traditionally, DME’s have been blocked out of this market by other manufacturers. But
now, AffloVest by International Biophysics offers an opportunity to you as well as your
patients with serious lung diseases — both your patients and your business will benefit
from this exciting new technology.
Resources provided by International Biophysics:
•Sales and Marketing support
•Billing/Insurance Support
•Clinical and Technological Education
•Sample protocols for Accreditation, Best Practices, etc.
•Full Education Support
Change in reimbursement rates for 2016*
E1390
E0601
E0464
AffloVest=
*E0464 becomes E0466 in 2016
www.afflovest.com
3
It’s time to offer your Patients and Clinicians
the AffloVest
•The AffloVest is the latest in HFCWO technology
•Freedom of movement without external air hoses or bulky generators
•9 setting variations for individualized treatment
•7 sizes available
•Quiet and lightweight
•Medicare, Medicaid and Private Insurance reimbursed*
•Third party clinical case studies highlighting quantitative improvements**
Nationwide need for effective
oscillation treatment options
• Estimated 10 million patient
population
• Improved quality of life for CF, ALS,
MS, Quadriplegia and other patients
• Improved treatment compliance
• Soaring and costly readmission rates
• Can reduce inpatient hospital time
• Reductions in exacerbations may lead to less
readmissions.
Insurance Landscape
• HCPCS Code E0483
• Currently reimbursed by Medicare, Medicaid and other
private insurers*
• Thousands of AffloVests already
in use in the U.S.
* Patients must qualify to meet eligibility requirements.
** C
ooper,Michael, RT. An evidence-based study of adolescents with cystic fi brosis demonstrated that
AffloVest By International Biophysics contributed to improved lung function scores. Chicago, IL.
Tackett, Michelle, RRT, Henderson, Vivian, RRT. Lung function improvement with AffloVest HFCWO use:
a clinician’s perspective on PFT score data from 25 patients with cystic fibrosis. Knoxville, TN.
4
AffloVest: DME Value Proposition
Growth Market: Bronchiectasis
• According to the American Lung Association, “In 2011, 12.7 million U.S. adults (aged
18 and over) were estimated to have COPD. However, close to 24 million U.S. adults
have evidence of impaired lung function, indicating an under diagnosis of COPD.”
• According to the Centers for Disease Control and Prevention (CDC)
www.cdc.gov/copd/index.html “Chronic lower respiratory disease, primarily COPD,
was the third leading cause of death in the United States in 2011. Fifteen million
Americans report that they have been diagnosed with COPD. More than 50% of adults
with low pulmonary function were not aware that they had COPD, therefore the actual
number may be higher.”
• Of the 15 million people with COPD, studies estimate that up to 57.6% may
have Bronchiectasis, a potential U.S. patient market of 8,640,000. If identified and
diagnosed (via a CT scan) with Bronchiectasis, it opens the door for these patients to
become eligible for reimbursed, insurance covered Airway Clearance Treatments (ACT)
such as the AffloVest.
How many of your
chronic lung
infection
patients have
Bronchiectasis?
www.afflovest.com
5
No loud, heavy
generators or being
tethered to hoses and
electrical outlets
No
Carts
COMPETITIVE COMPARISION CHART
Features
by International Biophysics
SmartVest®
Electromed, Inc.
The Vest®
Hill-Rom
inCourage®
RespirTech®
Multiple Power
Supply Options
Yes
Rechargeable Battery, AC & DC
No
AC Only
No
AC Only
No
AC Only
Weight
5-12 Lbs depending on size
(Including 8 oz. battery)
17 Lbs
(Generator only)
17 Lbs
(Generator only)
17 Lbs
(Generator only)
DC Charging Capabilities
Yes
No
No
No
Air Generator Required
No
Yes
Yes
Yes
Hoses Required
No hoses required
Yes
Yes
Yes
Electrical Outlet Required
No
Yes
Yes
Yes
Can Easily Use with Postural
Drainage Techniques
Yes
No
No
No
Targeting of Specific Lobe
or Chest Wall Region
Yes
No
No
No
External oscillation generator
and hoses connected to air
bladder vest
External oscillation generator
and hoses connected to air
bladder vest
External oscillation generator
and hoses connected to air
bladder vest
No Generator Required
Mode of Operation
8 Oscillation motors positioned
into AffloVest creating 8 individual
oscillation pressure waves
Air Filter
No (Air filter not required)
Yes
Yes
Yes
Warranty*
Yes
Yes
Yes
Yes
Easy-Read Hand-Held Digital
Programmable Controller
Yes
Attached to AffloVest
No
No
No
Medicare, Medicaid
and Private Insurance
Reimbursed**
Yes
Yes
Yes
Yes
Available to all Home Medical
Equipment Companies
Yes
No
No
No
* The AffloVest has a limited lifetime warranty, excluding the battery & accessories which have a five (5) year warranty. The travel case has a 1 year warranty.
For information on warranty coverage from other manufacturers, please contact that manufacturer for details.
** Patients must qualify to meet eligibility requirements.
AffloVest vs. Hill-Rom’s the Vest™
Noise Levels in Decibels
Decibels at 1 Meter (3.3 feet)
75
AffloVest
Hill-Rom™
70
65
60
45
62
45
47
48
30
15
0
AffloVest
Soft
Medium
Intense
(P2-Vibrate)
45 dB
47 dB
48 dB
-––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––--–––
Hill-Rom™
5 Hz
13 Hz
20 Hz
(Setting of 10)
62 dB
65 dB
70 dB
6
AffloVest: DME Value Proposition
So….how many referrals for
a specific piece of equipment
would a DME have to
process in order to equal
Please contact International
Biophysics for a VALUE
PROPOSITION WORKSHEET that
can show you how the Afflovest
can help offset current losses due
to competitive bidding.
the reimbursement for one
AffloVest? See for yourself
(based on Texas Medicare reimbursement rates).
HCPCS
PRODUCT
QTY = 1 VEST
E0143
Walker, folding, wheeled
186.9
A7030
Full Face Mask
108.4
K0001
Standard Wheelchair
27.5
K0003
Lightweight Wheelchair
16.9
E0601
CPAP
16.1
E0250
Hospital Bed, fixed
14.8
E0260
Hospital Bed, semi electric
11.6
K0813
Power Wheelchair, Group 1
3.8
K0820
Power Wheelchair, Group 2
3.6
E1390
Oxygen concentrator,
stationary
3.1
E0471
Respiratory Assist Device,
Bi-level Pressure w/ back up
2.9
E0193
Low Air Loss Mattress
1.5
E0483
AffloVest
1
www.afflovest.com
“It was liberating and made me
feel very free, unconstricted by
my disease.”
“…this airway clearance device is
medically necessary, and cannot
be substituted.”
“The AffloVest will offer this
patient the best chance to
remain healthy, to develop good
habits of treatment adherence,
and eventually to self-manage
his secretion clearance needs
without reliance upon others.”
The AffloVest is designed for
physician prescribed treatment of:
ALS, Bronchiectasis, Cystic Fibrosis,
Multiple Sclerosis, Muscular
Dystrophy, Primary Ciliary Dyskinesia
(PCD), Post Lung Transplant, Spinal
Cord Injury.
7
AffloVest Program Information
•Limited Lifetime Warranty
Lifetime Warranty on Afflovest and
motors and 5 year warranty on
accessories, including battery. One
year warranty on Travel Case
•30 Day Money Back Guarantee
•Inventory Exchange Program
•Loaner Program
•Leasing Options
•Patient Size Growth
Exchange Program
Breathe Better. Be Free.
• AffloVest is the first truly portable HFCWO
• Programmable treatments
• Shown to contribute to improved lung function scores*
• Easy-to-do daily required treatments
• Digital compliance meter
*C
ooper,Michael, RT. An evidence-based study of adolescents with cystic fi brosis
demonstrated that AffloVest By International Biophysics contributed to improved lung
function scores. Chicago, IL.
Tackett, Michelle, RRT, Henderson, Vivian, RRT. Lung function improvement with AffloVest
HFCWO use: a clinician’s perspective on PFT score data from 25 patients with cystic
fibrosis. Knoxville, TN.
International Biophysics Corporation
2101 E. St. Elmo Rd. Ste. 275 | Austin, TX 78744 | (T) 888-711-1145 | (F) 888-793-2319 | AffloVest.com | [email protected]
© Copyright 2016 International Biophysics Corporation. All rights reserved.
MKT0023 Rev A